Relevance of Immune Infiltration and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma Subtypes

Relevance of Immune Infiltration and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma Subtypes

PurposePancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with high heterogeneity and dismal survival rates. Tumor immune microenvironment plays a critical role in sensitive to chemotherapy and prognosis. Herein, we determined the relevance of the composition of tumor-infiltrating immune cel...

Full description

Bibliographic Details
Main Authors:	Rong Liu, Ya-Zhou Liao, Wei Zhang, Hong-Hao Zhou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-01-01
Series:	Frontiers in Oncology
Subjects:	tumor-immune infiltration pancreatic ductal adenocarcinoma overall survival relapse free survival M0 macrophages
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2020.575264/full

Similar Items

Development and Validation of a 7-Gene Prognostic Signature to Improve Survival Prediction in Pancreatic Ductal Adenocarcinoma
by: Zengyu Feng, et al.
Published: (2021-05-01)

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
by: He Xu, et al.
Published: (2021-02-01)

Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma
by: Yalu Zhang, et al.
Published: (2021-06-01)

A Long Non-coding RNA Signature to Improve Prognostic Prediction of Pancreatic Ductal Adenocarcinoma
by: Chenhao Zhou, et al.
Published: (2019-11-01)

Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit From Chemotherapy: A Propensity Score Matching Study
by: Yuchao Zhang, et al.
Published: (2020-07-01)

Phosphomannose Isomerase High Expression Associated with Better Prognosis in Pancreatic Ductal Adenocarcinoma
by: Alipour Z, et al.
Published: (2021-09-01)

Glycolysis-Related Gene Expression Profiling Screen for Prognostic Risk Signature of Pancreatic Ductal Adenocarcinoma
by: Wenjing Song, et al.
Published: (2021-06-01)

Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma
by: Dingyuan Hu, et al.
Published: (2019-02-01)

The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma
by: Li S, et al.
Published: (2019-04-01)

Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma
by: Ge Li, et al.
Published: (2020-05-01)

Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis
by: Dan Wang, et al.
Published: (2020-05-01)

Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review
by: Yizhi Wang, et al.
Published: (2020-09-01)

Vascular resection for locally advanced pancreatic ductal adenocarcinoma: analysis of long-term outcomes from a single-centre series
by: Claudio F. Feo, et al.
Published: (2021-04-01)

Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes
by: Andrea N. Riner, et al.
Published: (2020-06-01)

Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study
by: Rong Liu, et al.
Published: (2021-06-01)

The Prognostic Value of Preoperative Geriatric Nutritional Risk Index in Patients with Pancreatic Ductal Adenocarcinoma
by: Hu SP, et al.
Published: (2020-01-01)

CT texture features are associated with overall survival in pancreatic ductal adenocarcinoma – a quantitative analysis
by: Armin Eilaghi, et al.
Published: (2017-06-01)

Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma
by: Sohei Satoi, et al.
Published: (2020-01-01)

Comparative effectiveness of primary tumor resection in patients with stage III pancreatic adenocarcinoma
by: Ke Sun, et al.
Published: (2019-08-01)

A nomogram predicting overall survival in patients with non-metastatic pancreatic head adenocarcinoma after surgery: a population-based study
by: Wenbo Zou, et al.
Published: (2021-05-01)

Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis
by: Ke Zhang, et al.
Published: (2020-06-01)

The landscape of immune cell infiltration and its clinical implications of pancreatic ductal adenocarcinoma
by: Caiming Xu, et al.
Published: (2020-07-01)

Tumor location as an indicator of survival in T1 resectable pancreatic ductal adenocarcinoma: a propensity score-matched analysis
by: Zibo Meng, et al.
Published: (2019-04-01)

The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications
by: Xiaomeng Liu, et al.
Published: (2019-12-01)

Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker
by: Byeong Geun Song, et al.
Published: (2021-02-01)

Metastatic pancreatic adenocarcinomas could be classified into M1a and M1b category by the number of metastatic organs
by: Fang Feng, et al.
Published: (2020-08-01)

Long-term survival after resections for pancreatic ductal adenocarcinoma. Single centre study
by: Martin Lovecek, et al.
Published: (2016-06-01)

Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma
by: Dingyuan Hu, et al.
Published: (2018-11-01)

A feasible CT feature to differentiate focal‐type autoimmune pancreatitis from pancreatic ductal adenocarcinoma
by: Chaobin He, et al.
Published: (2019-10-01)

The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer
by: Meng Guo, et al.
Published: (2016-07-01)

C-Reactive Protein/Albumin Ratio and Prognostic Nutritional Index Are Strong Prognostic Indicators of Survival in Resected Pancreatic Ductal Adenocarcinoma
by: Masahide Ikeguchi, et al.
Published: (2017-07-01)

Transducin-Like Enhancer of Split-1 Inhibits Malignant Behaviors in vitro and Predicts a Better Prognosis in Pancreatic Ductal Adenocarcinoma
by: Yizhi Wang, et al.
Published: (2020-05-01)

The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor
by: Saber Amin, et al.
Published: (2020-09-01)

Analysis of Immune-Related Signatures Related to CD4+ T Cell Infiltration With Gene Co-Expression Network in Pancreatic Adenocarcinoma
by: Zhen Tan, et al.
Published: (2021-07-01)

Identification of prognostic splicing factors and exploration of their potential regulatory mechanisms in pancreatic adenocarcinoma
by: Min-hua Rong, et al.
Published: (2020-02-01)

Long-term survival after hepatectomy for metachronous liver metastasis of pancreatic ductal adenocarcinoma: a case report
by: Chikanori Tsutsumi, et al.
Published: (2020-07-01)

Correlation Between Enhancement Patterns on Transabdominal Ultrasound and Survival for Pancreatic Ductal Adenocarcinoma
by: Zhou T, et al.
Published: (2021-08-01)

Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma
by: Wen-Jing Liu, et al.
Published: (2018-01-01)

Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with Pancreatic Ductal Adenocarcinoma
by: Maximilian Brunner, et al.
Published: (2020-03-01)

High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma
by: Maria Cristina Curia, et al.
Published: (2019-05-01)